How many courses of treatment are generally required for Zanubrutinib? Does it need to be taken for life?

The number of courses of Zanubrutinib (Zanubrutinib) is based on the patient's specific condition, disease type and disease stage and therefore will vary from person to person. For some patients, zanubrutinib may need to be continued until the disease is effectively controlled or a longer remission is achieved. In the treatment of hematologic malignancies such as lymphoma, zanubrutinib is often administered as part of a maintenance regimen to control disease progression and prolong survival. This means patients may need to take zanubrutinib long-term until their doctor deems it appropriate to stop treatment.

The geometric mean (%CV) of zanubrutinib steady-state daily AUC was 2099 (42%) ng-h/mL after 160 mg twice daily dosing and 1917 (59%) ng-h/mL after 320 mg once-daily dosing. The geometric mean (%CV) of zanubrutinib steady-stateCmax was 295 (55%) ng/mL after 160 mg twice daily dosing and 537 (55%) ng/mL after 320 mg once daily dosing. The reason for lifelong use of zanubrutinib is that the drug inhibits the growth and spread of cancer cells, helping patients control disease progression and prolong survival.

However, specific treatment options will vary based on individual circumstances, including the stage of the disease, the patient's overall health, and the availability of other treatment options. For most patients, zanubrutinib needs to be taken for life. Zanubrutinib is a continuous treatment commonly used to control and manage certain types of hematologic malignancies, such as lymphoma. This means that patients need to continue taking medications every day as directed by their doctor to maintain a stable state of the disease or relieve symptoms.

The original drug of zanubrutinib has been launched in China and has been included in the medical insurance. The price of 80mg*64 capsules per box may be around 6,000 yuan. The original drug of zanubrutinib marketed overseas is relatively expensive. There are currently no generic drugs of zanubrutinib on the market.